The clinical efficacy of angiotensin II type1 receptor blockers on inflammatory markers in patients with hypertension: a multicenter randomized-controlled trial; MUSCAT-3 study

Ryoko Umebayashi, Haruhito Adam Uchida, Yuka Okuyama, Yuki Kakio, Yoshihisa Hanayama, Kenichi Shikata, Jun Wada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: The purpose of present study was to evaluate the clinical efficacy of irbesartan on the anti-inflammatory and anti-oxidative stress effect in patients with hypertension compared to other ARBs. Further, we assessed the effect of the ARBs on kidney function and urinary albumin excretion. Methods: Eighty-five outpatients with hypertension who took an ARB except irbesartan more than 3 months were assigned into two groups, one continued the same ARB and the other switched the ARB to irbesartan for 6 months. Results: Although blood pressures were equally controlled (continue group: 148 ± 2/79 ± 2 mmHg to 131 ± 2/74 ± 2 mmHg; switch group: 152 ± 2/81 ± 2 mmHg to 132 ± 2/74 ± 2 mmHg; p < 0.001 each), the inflammatory markers (hsCRP, PTX3, MCP-1) and oxidative stress marker (MDA-LDL) did not change after 6 months in both groups. Urinary albumin excretion was significantly reduced only in the switch group without renal function deterioration (switch group 292.4 ± 857.9 mg/gCr to 250.6 ± 906.5 mg/gCr, p = 0.012). Conclusion: These results provide knowledge of the characteristics of irbesartan, suggesting appropriate choice of ARBs in the treatment for hypertension should be considered.

Original languageEnglish
JournalBiomarkers
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

irbesartan
Angiotensin Receptor Antagonists
Randomized Controlled Trials
Hypertension
Oxidative stress
Switches
Albumins
Oxidative Stress
Kidney
Blood pressure
Deterioration
Anti-Inflammatory Agents
Outpatients
Blood Pressure

Keywords

  • albuminuria
  • Angiotensin II receptor blocker
  • hypertension
  • inflammation
  • oxidative stress

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis

Cite this

@article{50c6547d1633472e8a4c0baca2374312,
title = "The clinical efficacy of angiotensin II type1 receptor blockers on inflammatory markers in patients with hypertension: a multicenter randomized-controlled trial; MUSCAT-3 study",
abstract = "Purpose: The purpose of present study was to evaluate the clinical efficacy of irbesartan on the anti-inflammatory and anti-oxidative stress effect in patients with hypertension compared to other ARBs. Further, we assessed the effect of the ARBs on kidney function and urinary albumin excretion. Methods: Eighty-five outpatients with hypertension who took an ARB except irbesartan more than 3 months were assigned into two groups, one continued the same ARB and the other switched the ARB to irbesartan for 6 months. Results: Although blood pressures were equally controlled (continue group: 148 ± 2/79 ± 2 mmHg to 131 ± 2/74 ± 2 mmHg; switch group: 152 ± 2/81 ± 2 mmHg to 132 ± 2/74 ± 2 mmHg; p < 0.001 each), the inflammatory markers (hsCRP, PTX3, MCP-1) and oxidative stress marker (MDA-LDL) did not change after 6 months in both groups. Urinary albumin excretion was significantly reduced only in the switch group without renal function deterioration (switch group 292.4 ± 857.9 mg/gCr to 250.6 ± 906.5 mg/gCr, p = 0.012). Conclusion: These results provide knowledge of the characteristics of irbesartan, suggesting appropriate choice of ARBs in the treatment for hypertension should be considered.",
keywords = "albuminuria, Angiotensin II receptor blocker, hypertension, inflammation, oxidative stress",
author = "Ryoko Umebayashi and Uchida, {Haruhito Adam} and Yuka Okuyama and Yuki Kakio and Yoshihisa Hanayama and Kenichi Shikata and Jun Wada",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/1354750X.2018.1548033",
language = "English",
journal = "Biomarkers",
issn = "1354-750X",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - The clinical efficacy of angiotensin II type1 receptor blockers on inflammatory markers in patients with hypertension

T2 - a multicenter randomized-controlled trial; MUSCAT-3 study

AU - Umebayashi, Ryoko

AU - Uchida, Haruhito Adam

AU - Okuyama, Yuka

AU - Kakio, Yuki

AU - Hanayama, Yoshihisa

AU - Shikata, Kenichi

AU - Wada, Jun

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: The purpose of present study was to evaluate the clinical efficacy of irbesartan on the anti-inflammatory and anti-oxidative stress effect in patients with hypertension compared to other ARBs. Further, we assessed the effect of the ARBs on kidney function and urinary albumin excretion. Methods: Eighty-five outpatients with hypertension who took an ARB except irbesartan more than 3 months were assigned into two groups, one continued the same ARB and the other switched the ARB to irbesartan for 6 months. Results: Although blood pressures were equally controlled (continue group: 148 ± 2/79 ± 2 mmHg to 131 ± 2/74 ± 2 mmHg; switch group: 152 ± 2/81 ± 2 mmHg to 132 ± 2/74 ± 2 mmHg; p < 0.001 each), the inflammatory markers (hsCRP, PTX3, MCP-1) and oxidative stress marker (MDA-LDL) did not change after 6 months in both groups. Urinary albumin excretion was significantly reduced only in the switch group without renal function deterioration (switch group 292.4 ± 857.9 mg/gCr to 250.6 ± 906.5 mg/gCr, p = 0.012). Conclusion: These results provide knowledge of the characteristics of irbesartan, suggesting appropriate choice of ARBs in the treatment for hypertension should be considered.

AB - Purpose: The purpose of present study was to evaluate the clinical efficacy of irbesartan on the anti-inflammatory and anti-oxidative stress effect in patients with hypertension compared to other ARBs. Further, we assessed the effect of the ARBs on kidney function and urinary albumin excretion. Methods: Eighty-five outpatients with hypertension who took an ARB except irbesartan more than 3 months were assigned into two groups, one continued the same ARB and the other switched the ARB to irbesartan for 6 months. Results: Although blood pressures were equally controlled (continue group: 148 ± 2/79 ± 2 mmHg to 131 ± 2/74 ± 2 mmHg; switch group: 152 ± 2/81 ± 2 mmHg to 132 ± 2/74 ± 2 mmHg; p < 0.001 each), the inflammatory markers (hsCRP, PTX3, MCP-1) and oxidative stress marker (MDA-LDL) did not change after 6 months in both groups. Urinary albumin excretion was significantly reduced only in the switch group without renal function deterioration (switch group 292.4 ± 857.9 mg/gCr to 250.6 ± 906.5 mg/gCr, p = 0.012). Conclusion: These results provide knowledge of the characteristics of irbesartan, suggesting appropriate choice of ARBs in the treatment for hypertension should be considered.

KW - albuminuria

KW - Angiotensin II receptor blocker

KW - hypertension

KW - inflammation

KW - oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=85057585448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057585448&partnerID=8YFLogxK

U2 - 10.1080/1354750X.2018.1548033

DO - 10.1080/1354750X.2018.1548033

M3 - Article

C2 - 30444137

AN - SCOPUS:85057585448

JO - Biomarkers

JF - Biomarkers

SN - 1354-750X

ER -